Related Experiment Video
Updated: Dec 7, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Lorlatinib induced proteinuria: A case report
Chung-Shien Lee1,2, Rimda Wanchoo3, Nagashree Seetharamu2
1Department of Clinical Health Professions, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Introduction:
Lorlatinib is an oral anaplastic lymphoma kinase (ALK) and C-ros oncogene (ROS1) tyrosine kinase inhibitor with excellent central nervous system (CNS) penetrability. It is currently approved for use as second line therapy for those with ALK positive non-small cell lung cancer (NSCLC). Given its CNS penetrating effects, lorlatinib has shown to cause CNS adverse events such as seizures, hallucinations, and changes in cognitive function. To our knowledge proteinuria has not been previously described with this medication.
Case Report:
We report a case lorlatinib induced proteinuria in a patient receiving lorlatinib as second line treatment for ROS1 rearranged NSCLC.Management & Outcome: The patient's dose was reduced from 100 mg to 75 mg and further down to to 50 mg daily. At that point the proteinuria improved. Other adverse events attributable to the medication, specifically hallucinations and peripheral neuropathy also improved.
Discussion:
Our case demonstrates objective evidence for proteinuria induced by lorlatinib, which may also be dose dependent.
Insights
Lorlatinib, used for non-small cell lung cancer (NSCLC), may cause proteinuria. Reducing the lorlatinib dose improved this side effect, suggesting a dose-dependent relationship.
Area of Science:
- Oncology
- Pharmacology
Background:
- Lorlatinib is an ALK/ROS1 tyrosine kinase inhibitor for ALK-positive NSCLC.
- It has excellent CNS penetrability, leading to CNS adverse events.
- Proteinuria has not been previously reported with lorlatinib.
Observation:
- A case of lorlatinib-induced proteinuria in a patient with ROS1-rearranged NSCLC is presented.
- The patient experienced proteinuria while on second-line lorlatinib therapy.
Findings:
- Proteinuria improved with dose reduction of lorlatinib (100mg to 75mg, then 50mg daily).
- Other adverse events, including hallucinations and peripheral neuropathy, also improved.
Implications:
- This case provides evidence of lorlatinib-induced proteinuria.
- The proteinuria appears to be dose-dependent, suggesting a potential management strategy.
More Related Videos
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
10:15Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome III : Nursing Management
Serum Studies: Renal Function Tests
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...